-DOCSTART- -X- O
Objective -X- _ O
To -X- _ O
investigate -X- _ O
the -X- _ O
intention -X- _ O
of -X- _ O
the -X- _ O
Hong -X- _ B-Patient
Kong -X- _ I-Patient
general -X- _ I-Patient
population -X- _ I-Patient
to -X- _ O
take -X- _ O
up -X- _ O
vaccination -X- _ B-Intervention
against -X- _ I-Intervention
influenza -X- _ I-Intervention
A -X- _ I-Intervention
/ -X- _ I-Intervention
H1N1. -X- _ I-Intervention
Setting -X- _ O
Cross -X- _ O
sectional -X- _ O
population -X- _ O
based -X- _ O
anonymous -X- _ O
survey. -X- _ O
Participants -X- _ O
Random -X- _ O
sample -X- _ O
of -X- _ O
301 -X- _ O
adults -X- _ O
interviewed -X- _ O
by -X- _ O
telephone -X- _ O
( -X- _ O
response -X- _ O
rate -X- _ O
80 -X- _ O
% -X- _ O
) -X- _ O
. -X- _ O
Main -X- _ O
outcome -X- _ O
measure -X- _ O
Intention -X- _ O
to -X- _ O
take -X- _ O
up -X- _ O
vaccination -X- _ B-Intervention
against -X- _ I-Intervention
influenza -X- _ I-Intervention
A -X- _ I-Intervention
/ -X- _ I-Intervention
H1N1 -X- _ I-Intervention
under -X- _ O
five -X- _ O
hypothetical -X- _ O
scenarios -X- _ O
: -X- _ O
vaccination -X- _ O
is -X- _ O
free -X- _ O
; -X- _ O
vaccination -X- _ O
per -X- _ O
dosage -X- _ O
costs -X- _ O
less -X- _ O
than -X- _ O
$ -X- _ O
HK100 -X- _ O
( -X- _ O
£8 -X- _ O
; -X- _ O
€9 -X- _ O
; -X- _ O
$ -X- _ O
13 -X- _ O
) -X- _ O
, -X- _ O
$ -X- _ O
HK101-200 -X- _ O
, -X- _ O
or -X- _ O
more -X- _ O
than -X- _ O
$ -X- _ O
HK200 -X- _ O
; -X- _ O
and -X- _ O
no -X- _ O
data -X- _ O
are -X- _ O
available -X- _ O
on -X- _ O
the -X- _ O
efficacy -X- _ O
and -X- _ O
safety -X- _ O
of -X- _ O
the -X- _ O
vaccine. -X- _ O
Results -X- _ B-Outcome
45 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
n=135 -X- _ I-Outcome
) -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
participants -X- _ I-Outcome
reported -X- _ I-Outcome
that -X- _ I-Outcome
they -X- _ I-Outcome
would -X- _ I-Outcome
be -X- _ I-Outcome
highly -X- _ I-Outcome
likely -X- _ I-Outcome
take -X- _ I-Outcome
up -X- _ I-Outcome
vaccination -X- _ I-Outcome
if -X- _ I-Outcome
it -X- _ I-Outcome
was -X- _ I-Outcome
free. -X- _ I-Outcome
When -X- _ I-Outcome
vaccination -X- _ I-Outcome
incurred -X- _ I-Outcome
a -X- _ I-Outcome
cost -X- _ I-Outcome
, -X- _ I-Outcome
however -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
prevalence -X- _ I-Outcome
of -X- _ I-Outcome
uptake -X- _ I-Outcome
decreased -X- _ I-Outcome
: -X- _ I-Outcome
36 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
n=108 -X- _ I-Outcome
) -X- _ I-Outcome
would -X- _ I-Outcome
take -X- _ I-Outcome
up -X- _ I-Outcome
vaccination -X- _ I-Outcome
if -X- _ I-Outcome
it -X- _ I-Outcome
cost -X- _ I-Outcome
less -X- _ I-Outcome
than -X- _ I-Outcome
$ -X- _ I-Outcome
HK100 -X- _ I-Outcome
, -X- _ I-Outcome
24 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
n=72 -X- _ I-Outcome
) -X- _ I-Outcome
if -X- _ I-Outcome
it -X- _ I-Outcome
cost -X- _ I-Outcome
$ -X- _ I-Outcome
HK101-200 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
15 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
n=45 -X- _ I-Outcome
) -X- _ I-Outcome
if -X- _ I-Outcome
it -X- _ I-Outcome
cost -X- _ I-Outcome
more -X- _ I-Outcome
than -X- _ I-Outcome
$ -X- _ I-Outcome
HK200 -X- _ I-Outcome
; -X- _ I-Outcome
and -X- _ I-Outcome
in -X- _ I-Outcome
absence -X- _ I-Outcome
of -X- _ I-Outcome
proved -X- _ I-Outcome
efficacy -X- _ I-Outcome
and -X- _ I-Outcome
safety -X- _ I-Outcome
decreased -X- _ I-Outcome
to -X- _ I-Outcome
5 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
n=14 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Moreover -X- _ I-Outcome
, -X- _ I-Outcome
32 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
n=95 -X- _ I-Outcome
) -X- _ I-Outcome
considered -X- _ I-Outcome
universal -X- _ I-Outcome
A -X- _ I-Outcome
/ -X- _ I-Outcome
H1N1 -X- _ I-Outcome
vaccination -X- _ I-Outcome
unnecessary. -X- _ I-Outcome
Overall -X- _ I-Outcome
, -X- _ I-Outcome
39 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
n=117 -X- _ I-Outcome
) -X- _ I-Outcome
of -X- _ I-Outcome
participants -X- _ I-Outcome
believed -X- _ I-Outcome
that -X- _ I-Outcome
A -X- _ I-Outcome
/ -X- _ I-Outcome
H1N1 -X- _ I-Outcome
vaccination -X- _ I-Outcome
would -X- _ I-Outcome
prevent -X- _ I-Outcome
the -X- _ I-Outcome
virus -X- _ I-Outcome
being -X- _ I-Outcome
contracted -X- _ I-Outcome
; -X- _ I-Outcome
63 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
n=189 -X- _ I-Outcome
) -X- _ I-Outcome
erroneously -X- _ I-Outcome
believed -X- _ I-Outcome
that -X- _ I-Outcome
efficacy -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
vaccine -X- _ I-Outcome
had -X- _ I-Outcome
been -X- _ I-Outcome
confirmed -X- _ I-Outcome
by -X- _ I-Outcome
clinical -X- _ I-Outcome
trials -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
16 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
n=49 -X- _ I-Outcome
) -X- _ I-Outcome
believed -X- _ I-Outcome
that -X- _ I-Outcome
it -X- _ I-Outcome
is -X- _ I-Outcome
necessary -X- _ I-Outcome
for -X- _ I-Outcome
everyone -X- _ I-Outcome
in -X- _ I-Outcome
Hong -X- _ I-Outcome
Kong -X- _ I-Outcome
to -X- _ I-Outcome
take -X- _ I-Outcome
up -X- _ I-Outcome
vaccination -X- _ I-Outcome
against -X- _ I-Outcome
influenza -X- _ I-Outcome
A -X- _ I-Outcome
/ -X- _ I-Outcome
H1N1. -X- _ I-Outcome
Conclusions -X- _ O
The -X- _ O
uptake -X- _ O
of -X- _ O
vaccination -X- _ B-Intervention
against -X- _ I-Intervention
influenza -X- _ I-Intervention
A -X- _ I-Intervention
/ -X- _ I-Intervention
H1N1 -X- _ I-Intervention
by -X- _ O
the -X- _ O
general -X- _ B-Patient
population -X- _ I-Patient
of -X- _ I-Patient
Hong -X- _ I-Patient
Kong -X- _ I-Patient
is -X- _ O
unlikely -X- _ B-Outcome
to -X- _ I-Outcome
be -X- _ I-Outcome
high -X- _ I-Outcome
and -X- _ I-Outcome
would -X- _ I-Outcome
be -X- _ I-Outcome
sensitive -X- _ I-Outcome
to -X- _ I-Outcome
personal -X- _ I-Outcome
cost. -X- _ I-Outcome
Evidence -X- _ O
about -X- _ O
safety -X- _ O
and -X- _ O
efficacy -X- _ O
is -X- _ O
critical -X- _ O
in -X- _ O
determining -X- _ O
the -X- _ O
prevalence -X- _ O
of -X- _ O
uptake -X- _ O
of -X- _ O
vaccination -X- _ O
. -X- _ O

